Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Hepatitis B · Mixed Dyslipidemia · ARWR

Arrowhead Pharmaceuticals Ireland

Arrowhead Pharmaceuticals Ireland Limited

Arrowhead Pharmaceuticals Ireland clinical programs — 30 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
177 E Colorado Blvd, Suite 700, Pasadena, California 91105, US HQ
746 Employees
Public company Type
ARWR · NYSE Ticker
Company details
Status
Public
HQ
177 E Colorado Blvd, Suite 700, Pasadena, California 91105, US
Employees
746
Programs
63
Drugs
34
Patents
126
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Arrowhead Pharmaceuticals Ireland projects

30 ClinicalTrials.gov programs sponsored by Arrowhead Pharmaceuticals Ireland.

Arrowhead Pharmaceuticals Ireland has 30 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

30 programs

Clinical programs

  1. 0.9% Sodium chloride - inhalation solution

    Arrowhead Pharmaceuticals Ireland Limited

    Inflammatory Lung Disease

    phase 2 small molecule active

    1 trial

  2. ARC-520

    Arrowhead Pharmaceuticals Ireland Limited

    Hepatitis B

    phase 2 small molecule terminated

    2 trials

  3. ARC-520

    Arrowhead Pharmaceuticals Ireland Limited

    Chronic Hepatitis B

    phase 2 small molecule terminated

    1 trial

  4. ARC-520

    Arrowhead Pharmaceuticals Ireland Limited

    Hepatitis B, Chronic

    phase 2 small molecule terminated

    1 trial

  5. ARC-520 Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Chronic Hepatitis B

    phase 2 small molecule terminated

    1 trial

  6. ARC-520 Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Hepatitis B

    phase 2 small molecule terminated

    2 trials

  7. ARC-AAT Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Alpha-1 Antitrypsin Deficiency

    phase 2 small molecule terminated

    2 trials

  8. ARO-AAT

    Arrowhead Pharmaceuticals Ireland Limited

    Alpha 1-Antitrypsin Deficiency

    phase 2 small molecule completed

    1 trial

  9. ARO-ALK7

    Arrowhead Pharmaceuticals Ireland Limited

    Obesity

    phase 2 small molecule active

    1 trial

  10. ARO-ANG 3 Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Homozygous Familial Hypercholesterolemia

    phase 2 small molecule terminated

    1 trial

  11. ARO-ANG3

    Arrowhead Pharmaceuticals Ireland Limited

    Mixed Dyslipidemia

    phase 2 small molecule completed

    1 trial

  12. ARO-APOC3

    Arrowhead Pharmaceuticals Ireland Limited

    Dyslipidemias

    phase 2 small molecule completed

    1 trial

  13. ARO-APOC3

    Arrowhead Pharmaceuticals Ireland Limited

    Severe Hypertriglyceridemia

    phase 2 small molecule completed

    1 trial

  14. ARO-APOC3

    Arrowhead Pharmaceuticals Ireland Limited

    Mixed Dyslipidemia

    phase 2 small molecule active

    1 trial

  15. ARO-APOC3

    Arrowhead Pharmaceuticals Ireland Limited

    Mixed Dyslipidemia

    phase 2 small molecule completed

    1 trial

  16. ARO-C3

    Arrowhead Pharmaceuticals Ireland Limited

    C3 Glomerulopathy

    phase 2 small molecule completed

    1 trial

  17. ARO-C3

    Arrowhead Pharmaceuticals Ireland Limited

    complement-mediated renal disease

    phase 2 small molecule active

    1 trial

  18. ARO-DIMERPA

    Arrowhead Pharmaceuticals Ireland Limited

    Hyperlipidemia; Mixed

    phase 2 small molecule active

    1 trial

  19. ARO-DM1 Intravenous (IV) Infusion

    Arrowhead Pharmaceuticals Ireland Limited

    Myotonic Dystrophy 1

    phase 2 small molecule active

    1 trial

  20. ARO-DUX4 for Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Facio-Scapulo-Humeral Dystrophy

    phase 2 small molecule active

    1 trial

  21. ARO-ENaC

    Arrowhead Pharmaceuticals Ireland Limited

    Cystic Fibrosis, Pulmonary

    phase 2 small molecule terminated

    1 trial

  22. ARO-HBV

    Arrowhead Pharmaceuticals Ireland Limited

    Hepatitis B

    phase 2 small molecule completed

    1 trial

  23. ARO-HSD Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Non-alcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial

  24. ARO-INHBE

    Arrowhead Pharmaceuticals Ireland Limited

    Obesity

    phase 2 small molecule active

    1 trial

  25. ARO-MAPT-SC

    Arrowhead Pharmaceuticals Ireland Limited

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  26. ARO-MMP7 Inhalation Solution

    Arrowhead Pharmaceuticals Ireland Limited

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule completed

    1 trial

  27. ARO-MUC5AC

    Arrowhead Pharmaceuticals Ireland Limited

    Asthma

    phase 2 small molecule terminated

    1 trial

  28. ARO-RAGE

    Arrowhead Pharmaceuticals Ireland Limited

    Asthma

    phase 2 small molecule active

    2 trials

  29. AROMUC5AC-1001

    Arrowhead Pharmaceuticals Ireland Limited

    Asthma and Chronic obstructive pulmonary disease

    phase 2 small molecule active

    1 trial

  30. Fazisiran Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Alpha 1-Antitrypsin Deficiency

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Arrowhead Pharmaceuticals Ireland have?

30 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.